Virtual Screening and Optimization of Novel mTOR Inhibitors for Radiosensitization of Hepatocellular Carcinoma

References

• ZallerN, Brinkley-RubinsteinL. Incarceration, drug use, and infectious diseases: a syndemic still not addressed. Lancet Infect Dis. 2018;18(12):1301–1302. doi:10.1016/S1473-3099(18)30538-330385159
   PubMed Web of Science ®Google Scholar
• FengF, JiangQ, JiaH, et al. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment A systematic review and network meta-analysis. Pharmacol Res. 2018;135:89–101. doi:10.1016/j.phrs.2018.06.02129959032
   PubMed Web of Science ®Google Scholar
• LiuR, ZhaoD, ZhangX, et al. A20 enhances the radiosensitivity of hepatocellular carcinoma cells to (60)Co-gamma ionizing radiation. Oncotarget. 2017;8(54):93103–93116. doi:10.18632/oncotarget.2186029190981
   PubMedGoogle Scholar
• ToyaR, MurakamiR, BabaY, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol. 2007;84(3):266–271. doi:10.1016/j.radonc.2007.07.00517716760
   PubMed Web of Science ®Google Scholar
• SongLL, PengY, YunJ, et al. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene. 2008;27(44):5833–5844. doi:10.1038/onc.2008.19018560356
   PubMed Web of Science ®Google Scholar
• CaoS, CaoR, LiuX, et al. Design, synthesis and biological evaluation of novel benzothiazole derivatives as selective PI3Kβ inhibitors. Molecules. 2016;21(7):876–890. doi:10.3390/molecules21070876
   PubMed Web of Science ®Google Scholar
• BarraF, EvangelistiG, Ferro DesideriL, et al. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 2019;28(2):131–142. doi:10.1080/13543784.2018.1558202
   PubMed Web of Science ®Google Scholar
• CortiF, NichettiF, RaimondiA, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives. Cancer Treat Rev. 2019;72:45–55. doi:10.1016/j.ctrv.2018.11.00130476750
   PubMed Web of Science ®Google Scholar
• SchmidP, ZaissM, Harper-WynneC, et al. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial. JAMA oncol. 2019;5(11):1556. doi:10.1001/jamaoncol.2019.2526
   PubMed Web of Science ®Google Scholar
• LapointeS, MasonW, MacNeilM, et al. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. Invest New Drugs. 2019. doi:10.1007/s10637-019-00875-4
   PubMed Web of Science ®Google Scholar
• BehbakhtK, SillMW, DarcyKM, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology group study. Gynecol Oncol. 2011;123(1):19–26. doi:10.1016/j.ygyno.2011.06.02221752435
   PubMed Web of Science ®Google Scholar
• YuK, ShiC, Toral-BarzaL, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010;70(2):621–631. doi:10.1158/0008-5472.CAN-09-234020068177
   PubMed Web of Science ®Google Scholar
• AtkinJ, HalovaL, FergusonJ, et al. Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells. J Cell Sci. 2014;127(Pt 6):1346–1356. doi:10.1242/jcs.14637324424027
   PubMed Web of Science ®Google Scholar
• YuK, Toral-BarzaL, ShiC, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009;69(15):6232–6240. doi:10.1158/0008-5472.CAN-09-029919584280
   PubMed Web of Science ®Google Scholar
• LiS, LiangY, WuM, et al. The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells. Cancer Cell Int. 2013;13:30. doi:10.1186/1475-2867-13-3023537100
   PubMed Web of Science ®Google Scholar
• LlerenaS, Garcia-DiazN, Curiel-OlmoS, et al. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget. 2018;9(56):30869–30882. doi:10.18632/oncotarget.2576630112114
   PubMedGoogle Scholar
• de MeloAC, PaulinoE, GarcesAH. A review of mTOR pathway inhibitors in gynecologic cancer. Oxid Med Cell Longev. 2017;2017:4809751. doi:10.1155/2017/480975128286604
   PubMed Web of Science ®Google Scholar
• SuzukiY, EnokidoY, YamadaK, et al. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS). Oncotarget. 2017;8(28):45470–45483. doi:10.18632/oncotarget.1756628525374
   PubMedGoogle Scholar
• SutherlinDP, BaoL, BerryM, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem. 2011;54(21):7579–7587. doi:10.1021/jm200932721981714
   PubMed Web of Science ®Google Scholar
• DjuzenovaCS, FiedlerV, KatzerA, et al. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of drug-irradiation schedule. Oncotarget. 2016;7(25):38191–38209. doi:10.18632/oncotarget.950127224913
   PubMedGoogle Scholar
• KahnJ, HaymanTJ, JamalM, et al. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro Oncol. 2014;16(1):29–37. doi:10.1093/neuonc/not13924311635
   PubMed Web of Science ®Google Scholar
• AlcornS, WalkerAJ, GandhiN, et al. Molecularly targeted agents as radiosensitizers in cancer therapy-focus on prostate cancer. Int J Mol Sci. 2013;14(7):14800–14832. doi:10.3390/ijms14071480023863691
   PubMed Web of Science ®Google Scholar
• ChangL, GrahamPH, NiJ, et al. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol. 2015;96:507–517. doi:10.1016/j.critrevonc.2015.07.00526253360
   PubMed Web of Science ®Google Scholar
• Benderli CihanY. Role of mTOR signaling pathway proteins and proteins influencing mTOR pathway in resistance to radiotherapy in prostate cancer. J BUON. 2018;23(6):1931–1932.
   PubMed Web of Science ®Google Scholar
• WenPY, OmuroA, AhluwaliaMS, et al. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol. 2015;17(9):1275–1283. doi:10.1093/neuonc/nov08326019185
   PubMed Web of Science ®Google Scholar
• LiuT, SunQ, LiQ, et al. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer Ther. 2015;14(2):429–439. doi:10.1158/1535-7163.MCT-14-054825504751
   PubMed Web of Science ®Google Scholar
• WangWJ, LongLM, YangN, et al. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Acta Pharmacol Sin. 2013;34(5):681–690. doi:10.1038/aps.2013.2223603977
   PubMed Web of Science ®Google Scholar
• HaymanTJ, WahbaA, RathBH, et al. The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells. Clin Cancer Res. 2014;20(1):110–119. doi:10.1158/1078-0432.CCR-13-213624198241
   PubMed Web of Science ®Google Scholar
• ShapiroGI, Bell-McGuinnKM, MolinaJR, et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res. 2015;21(8):1888–1895. doi:10.1158/1078-0432.CCR-14-130625652454
   PubMed Web of Science ®Google Scholar
• LeeW, OrtwineDF, BergeronP, et al. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors. Bioorg Med Chem Lett. 2013;23:5097–5104. doi:10.1016/j.bmcl.2013.07.02723932790
   PubMed Web of Science ®Google Scholar
• SongSH, JeongWK, ChoiD, et al. Evaluation of early treatment response to radiotherapy for HCC using pre- and post-treatment MRI. Acta Radiol. 2019;60(7):826–835. doi:10.1177/028418511880525330282483
   PubMed Web of Science ®Google Scholar
• YuJI, ChoiGS, LimDH, et al. Treatment of naive HCC combined with segmental or subsegmental portal vein tumor thrombosis: liver resection versus TACE followed by radiotherapy. Anticancer Res. 2018;38(8):4919–4925. doi:10.21873/anticanres.1280830061270
   PubMed Web of Science ®Google Scholar
• SuriOP, SattiNK, SuriKA. Microwave induced acetoacetylation of hetaryl and aryl amines. Synth Commun. 2000;30(20):3709–3718. doi:10.1080/00397910008086998
   Web of Science ®Google Scholar
• HafizISA, RamizMMM, SarhanAAM. Activated Anilide in heterocyclic synthesis: synthesis of new dihydropyridines, dihydropyridazines and thiourea derivatives. Chin J Chem. 2011;29(6):1154–1162. doi:10.1002/cjoc.201190216
   Web of Science ®Google Scholar
• CaballeroJ. 3D-QSAR (CoMFA and CoMSIA) and pharmacophore (GALAHAD) studies on the differential inhibition of aldose reductase by flavonoid compounds. J Mol Graph Model. 2010;29(3):363–371. doi:10.1016/j.jmgm.2010.08.00520863730
   PubMed Web of Science ®Google Scholar
• SchrodingerLLC The PyMOL molecular graphics system, version 1.8. 2015.
   Google Scholar
• SunN, LiB, ShaoJ, et al. A general and facile one-pot process of isothiocyanates from amines under aqueous conditions. Beilstein J Org Chem. 2012;8:61–70. doi:10.3762/bjoc.8.622423272
   PubMed Web of Science ®Google Scholar
• ChenY, FengF, GaoX, et al. MiRNA153 reduces effects of chemotherapeutic agents or small molecular kinase inhibitor in HCC cells. Curr Cancer Drug Targets. 2015;15(3):176–187. doi:10.2174/156800961566615022512263525714700
   PubMed Web of Science ®Google Scholar
• FengF, JiangQ, CaoS, et al. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. Biochim Biophys Acta Gen Subj. 2018;1862(4):1017–1030. doi:10.1016/j.bbagen.2018.01.01129369785
   PubMed Web of Science ®Google Scholar
• ZhangY, LiD, JiangQ, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018;9(7):743–756. doi:10.1038/s41419-018-0804-629970890
   PubMed Web of Science ®Google Scholar
• ShaoZ, LiY, DaiW, et al. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Pharmacol Res. 2018;135:188–200. doi:10.1016/j.phrs.2018.08.00330114438
   PubMed Web of Science ®Google Scholar
• FengY, XuX, ZhangY, et al. HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation, apoptosis and invasion. Sci Rep. 2015;5:9429–9440. doi:10.1038/srep0942925800793
   PubMed Web of Science ®Google Scholar
• LiuG, WangW, WanY, et al. Application of 3D-QSAR, pharmacophore, and molecular docking in the molecular design of diarylpyrimidine derivatives as HIV-1 nonnucleoside reverse transcriptase inhibitors. Int J Mol Sci. 2018;19(5):1436–1452. doi:10.3390/ijms19051436
   PubMed Web of Science ®Google Scholar
• LiuG, WanY, WangW, et al. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Mol Divers. 2019;23(1):107–121. doi:10.1007/s11030-018-9860-130051344
   PubMed Web of Science ®Google Scholar
• PeiZ, BlackwoodE, LiuL, et al. Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349. ACS Med Chem Lett. 2013;4(1):103–107. doi:10.1021/ml300313224900569
   PubMed Web of Science ®Google Scholar
• BhagwatSV, GokhalePC, CrewAP, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011;10(8):1394–1406. doi:10.1158/1535-7163.MCT-10-109921673091
   PubMed Web of Science ®Google Scholar
• QuemenerA, MaillassonM, ArzelL, et al. Discovery of a small-molecule inhibitor of interleukin 15: pharmacophore-based virtual screening and hit optimization. J Med Chem. 2017;60(14):6249–6272. doi:10.1021/acs.jmedchem.7b0048528657314
   PubMed Web of Science ®Google Scholar
• VerheijenJC, RichardDJ, CurranK, et al. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4−d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the Mammalian Target of Rapamycin (mTOR): optimization of the 6-Aryl substituent. J Med Chem. 2009;52(24):8010–8024. doi:10.1021/jm901382819894727
   PubMed Web of Science ®Google Scholar
• TongY, ZhuW, HuangX, et al. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncol Rep. 2014;31(4):1581–1588. doi:10.3892/or.2014.302024535016
   PubMed Web of Science ®Google Scholar
• YangX, YangJA, LiuBH, et al. TGX-221 inhibits proliferation and induces apoptosis in human glioblastoma cells. Oncol Rep. 2017;38(5):2836–2842. doi:10.3892/or.2017.599129048665
   PubMed Web of Science ®Google Scholar